Aarhus, Denmark, 23 July 2026 – NMD Pharma A/S, a clinical-stage biotechnology company focused on developing novel therapies to restore skeletal muscle health, today announced the publication of new clinical and preclinical research in The Journal of Clinical Investigation identifying neuromuscular junction (NMJ) transmission failure as a key and potentially reversible contributor to age-related muscle weakness and sarcopenia.